Advertisement
Australia markets close in 1 hour 5 minutes
  • ALL ORDS

    7,899.60
    +38.60 (+0.49%)
     
  • ASX 200

    7,643.40
    +37.80 (+0.50%)
     
  • AUD/USD

    0.6445
    +0.0008 (+0.12%)
     
  • OIL

    82.80
    +0.11 (+0.13%)
     
  • GOLD

    2,389.90
    +1.50 (+0.06%)
     
  • Bitcoin AUD

    95,766.88
    -3,962.59 (-3.97%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • AUD/EUR

    0.6033
    +0.0007 (+0.12%)
     
  • AUD/NZD

    1.0887
    +0.0014 (+0.13%)
     
  • NZX 50

    11,808.56
    -66.79 (-0.56%)
     
  • NASDAQ

    17,493.62
    -220.04 (-1.24%)
     
  • FTSE

    7,847.99
    +27.63 (+0.35%)
     
  • Dow Jones

    37,753.31
    -45.66 (-0.12%)
     
  • DAX

    17,770.02
    +3.79 (+0.02%)
     
  • Hang Seng

    16,469.29
    +217.45 (+1.34%)
     
  • NIKKEI 225

    38,077.68
    +115.88 (+0.31%)
     

Valeant Pharmaceuticals before Its Q2 2018 Earnings

Valeant Pharmaceuticals before Its Q2 2018 Earnings

Valeant Pharmaceuticals (VRX), now known as Bausch Health Companies (BHC), generated revenues of $2 billion in the first quarter compared to $2.1 billion in the first quarter of 2017, reflecting a 5% YoY (year-over-year) decline.